Polaryx Therapeutics

Company snapshot

Polaryx Therapeutics’ mission is to meet the large unmet need and accelerate the availability of treatments for patients and families living with lysosomal storage disorders (LSDs). Our pipeline is comprised of uniquely formulated refocused drugs, New Chemical Entities (NCE), and gene therapy candidates to treat these diseases. There is an urgent need for novel therapeutic interventions for LSDs,

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Polaryx Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Polaryx Therapeutics.

1. May 23, 2026 Clinical update

   PLX-200 — Phase 3

View all clinical trial activity →

• What is Polaryx Therapeutics?

  Polaryx Therapeutics is a pharma organization headquartered in Paramus, USA. It trades on NYSE under ticker PLYX. Primary therapeutic focus areas include Juvenile Neuronal Ceroid Lipofuscinosis. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s)

• Is Polaryx Therapeutics publicly traded?

  Yes. Polaryx Therapeutics is listed with ticker PLYX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Polaryx Therapeutics develop or market?

  No drug profiles are currently linked to Polaryx Therapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for Polaryx Therapeutics?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Polaryx Therapeutics focus on?

  Polaryx Therapeutics focuses on Juvenile Neuronal Ceroid Lipofuscinosis based on our analysis of their pipeline programs and drug development activities.